TNDM vs. NARI, IRTC, ICUI, PRCT, AXNX, NVCR, IART, LMAT, ATEC, and MDXG
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Inari Medical (NARI), iRhythm Technologies (IRTC), ICU Medical (ICUI), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Integra LifeSciences (IART), LeMaitre Vascular (LMAT), Alphatec (ATEC), and MiMedx Group (MDXG). These companies are all part of the "surgical & medical instruments" industry.
Inari Medical (NASDAQ:NARI) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Tandem Diabetes Care received 510 more outperform votes than Inari Medical when rated by MarketBeat users. However, 68.24% of users gave Inari Medical an outperform vote while only 61.01% of users gave Tandem Diabetes Care an outperform vote.
91.0% of Inari Medical shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Inari Medical had 26 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 29 mentions for Inari Medical and 3 mentions for Tandem Diabetes Care. Inari Medical's average media sentiment score of 1.00 beat Tandem Diabetes Care's score of 0.17 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
Inari Medical currently has a consensus price target of $65.71, suggesting a potential upside of 43.64%. Tandem Diabetes Care has a consensus price target of $43.80, suggesting a potential downside of 7.40%. Given Tandem Diabetes Care's higher possible upside, equities research analysts clearly believe Inari Medical is more favorable than Tandem Diabetes Care.
Inari Medical has higher earnings, but lower revenue than Tandem Diabetes Care. Inari Medical is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Inari Medical has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Inari Medical has a net margin of -4.54% compared to Inari Medical's net margin of -18.37%. Tandem Diabetes Care's return on equity of -1.65% beat Inari Medical's return on equity.
Summary
Inari Medical beats Tandem Diabetes Care on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
